Exhibit 10.2

KalVista Pharmaceuticals, Inc.

March 11, 2019

 

Dr. Christopher Yea

 

Dear Christopher:

You are party to a Service Agreement with KalVista Pharmaceuticals Limited, a
company incorporated and registered in England and Wales (“KVP UK”) and a
subsidiary of KalVista Pharmaceuticals, Inc., a Delaware corporation (“KVP US”),
dated as of November 1, 2015 and amended by a deed January 31, 2019 (the “UK
Service Agreement”),

If your employment is terminated by KVP UK (or its successor) during the two
year period immediately following a Change of Control (as defined in the UK
Service Agreement), and as a result of such termination you are entitled to the
Severance Pay set forth therein, then, in addition to the Severance Pay, all of
your then-unvested Equity Awards (as defined below) will vest in full (the
“Acceleration”).  This Acceleration is conditioned on your execution of a
settlement agreement releasing claims against the KVP US and its affiliates in a
form acceptable to KVP US (the “Release”) and on that Release becoming
irrevocable within 60 days following the termination date.  

“Equity Awards” means any stock options, restricted stock, restricted stock
units, stock appreciation rights, phantom stock or other equity based awards
granted by KVP US to you.  

Your eligibility to receive the Acceleration shall not create a right to further
employment with the KVP UK or KVP US, or the right to receive additional
equity.  Your rights under this letter agreements are entirely separate from any
rights you have under your terms and conditions of employment with KVP UK.  

 

Sincerely,

KalVista Pharmaceuticals, Inc.

By: /s/ Benjamin L. Palleiko

Name: Benjamin L. Palleiko        

Title:Chief Financial Officer____________